EA201590305A1 - PRODUCTION PRODUCT, INCLUDING AFLIBERCEPT OR ZIV-AFLIBERCEPT - Google Patents

PRODUCTION PRODUCT, INCLUDING AFLIBERCEPT OR ZIV-AFLIBERCEPT

Info

Publication number
EA201590305A1
EA201590305A1 EA201590305A EA201590305A EA201590305A1 EA 201590305 A1 EA201590305 A1 EA 201590305A1 EA 201590305 A EA201590305 A EA 201590305A EA 201590305 A EA201590305 A EA 201590305A EA 201590305 A1 EA201590305 A1 EA 201590305A1
Authority
EA
Eurasian Patent Office
Prior art keywords
aflibercept
ziv
production product
biosimilar
notifies
Prior art date
Application number
EA201590305A
Other languages
Russian (ru)
Inventor
Сильви Ассадуриан
Реми Кастан
Эмманюэлль Магерини
Original Assignee
Санофи
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санофи filed Critical Санофи
Publication of EA201590305A1 publication Critical patent/EA201590305A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1858—Platelet-derived growth factor [PDGF]
    • A61K38/1866—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
    • B65D85/00—Containers, packaging elements or packages, specially adapted for particular articles or materials
    • B65D85/70—Containers, packaging elements or packages, specially adapted for particular articles or materials for materials not otherwise provided for
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Mechanical Engineering (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Wrappers (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к изделию производства, включающему упаковочный материал, полипептид SEQ ID NO: 1, афлиберцепт или зив-афлиберцепт, или его биоаналог, и этикетку, включающую напечатанное сообщение, которое уведомляет предполагаемого потребителя о неблагоприятных явлениях или неблагоприятных реакциях.The invention relates to an article of manufacture comprising a packaging material, a polypeptide of SEQ ID NO: 1, aflibercept or ziv-aflibercept, or its biosimilar, and a label comprising a printed message that notifies the intended consumer of adverse events or adverse reactions.

EA201590305A 2012-08-02 2013-08-02 PRODUCTION PRODUCT, INCLUDING AFLIBERCEPT OR ZIV-AFLIBERCEPT EA201590305A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261678983P 2012-08-02 2012-08-02
US201261679490P 2012-08-03 2012-08-03
PCT/EP2013/066299 WO2014020160A1 (en) 2012-08-02 2013-08-02 Article of manufacture comprising aflibercept or ziv-aflibercept

Publications (1)

Publication Number Publication Date
EA201590305A1 true EA201590305A1 (en) 2015-06-30

Family

ID=48917540

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201590305A EA201590305A1 (en) 2012-08-02 2013-08-02 PRODUCTION PRODUCT, INCLUDING AFLIBERCEPT OR ZIV-AFLIBERCEPT

Country Status (17)

Country Link
US (2) US20150216795A1 (en)
EP (1) EP2879694A1 (en)
JP (1) JP2015526430A (en)
KR (1) KR20150038297A (en)
CN (1) CN104853763A (en)
AR (1) AR091967A1 (en)
AU (1) AU2013298521A1 (en)
CA (1) CA2888281A1 (en)
EA (1) EA201590305A1 (en)
HK (1) HK1206628A1 (en)
IL (1) IL236931A0 (en)
MX (1) MX2015001550A (en)
SG (1) SG11201500480TA (en)
TW (1) TW201408316A (en)
UY (1) UY34962A (en)
WO (1) WO2014020160A1 (en)
ZA (1) ZA201500485B (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2788949C1 (en) * 2019-12-06 2023-01-26 Ридженерон Фармасьютикалз, Инк. Protein compositions against vegf and methods for their preparation

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3283B1 (en) 2011-04-26 2018-09-16 Sanofi Sa Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)
AR095196A1 (en) 2013-03-15 2015-09-30 Regeneron Pharma SERUM FREE CELL CULTIVATION MEDIA
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
SG11201700284UA (en) 2014-07-18 2017-02-27 Sanofi Sa Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer
EP3310688A1 (en) 2015-06-17 2018-04-25 Novozymes A/S Container
TW202330904A (en) 2015-08-04 2023-08-01 美商再生元醫藥公司 Taurine supplemented cell culture medium and methods of use
KR101936049B1 (en) * 2015-10-15 2019-01-08 (주)알테오젠 Method for manufacturing fusion proteins with IgG Fc domain
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
WO2017129537A1 (en) * 2016-01-25 2017-08-03 Sanofi Method for predicting the outcome of a treatment with aflibercept of a patient suspected to suffer from a cancer by measuring the level of a plasma biomarker
TW201934570A (en) * 2017-07-06 2019-09-01 美商雷傑納榮製藥公司 Cell culture process for making a glycoprotein
CN109929038B (en) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 Purification method of VEGF (vascular endothelial growth factor) capture agent fusion protein
CN109929027B (en) * 2017-12-15 2020-10-09 山东博安生物技术有限公司 Method for purifying recombinant fusion protein by linear elution step
EP3863657A4 (en) * 2018-10-12 2022-07-20 Trican Biotechnology Co., Ltd Bi-functional fusion proteins and uses thereof
JP2022523063A (en) * 2019-01-30 2022-04-21 アムジエン・インコーポレーテツド Aflibercept attributes and their characterization and modification methods
EP4041312A4 (en) 2019-10-10 2023-12-20 Kodiak Sciences Inc. Methods of treating an eye disorder
JP2022548197A (en) 2019-12-06 2022-11-17 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ANTI-VEGF PROTEIN COMPOSITION AND METHOD FOR MANUFACTURE THEREOF

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1861116T3 (en) * 2005-03-25 2015-11-09 Regeneron Pharma VEGF antagonist formulations
JO3283B1 (en) * 2011-04-26 2018-09-16 Sanofi Sa Composition comprising aflibercept, folinic acid, 5-fluorouracil (5-fu) and irinocetan (folfiri)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2788949C1 (en) * 2019-12-06 2023-01-26 Ридженерон Фармасьютикалз, Инк. Protein compositions against vegf and methods for their preparation

Also Published As

Publication number Publication date
UY34962A (en) 2014-02-28
HK1206628A1 (en) 2016-01-15
CN104853763A (en) 2015-08-19
US20150216795A1 (en) 2015-08-06
WO2014020160A1 (en) 2014-02-06
ZA201500485B (en) 2017-07-26
CA2888281A1 (en) 2014-02-06
US20180078496A1 (en) 2018-03-22
KR20150038297A (en) 2015-04-08
TW201408316A (en) 2014-03-01
MX2015001550A (en) 2015-05-11
SG11201500480TA (en) 2015-02-27
AU2013298521A1 (en) 2015-02-26
IL236931A0 (en) 2015-03-31
AR091967A1 (en) 2015-03-11
EP2879694A1 (en) 2015-06-10
JP2015526430A (en) 2015-09-10

Similar Documents

Publication Publication Date Title
EA201590305A1 (en) PRODUCTION PRODUCT, INCLUDING AFLIBERCEPT OR ZIV-AFLIBERCEPT
MX2019007024A (en) Improved plastic degrading proteases.
MX2020006359A (en) Novel proteases and uses thereof.
MX2023011423A (en) Novel esterases and uses thereof.
MX2015007423A (en) Fragrance materials.
TN2017000085A1 (en) Polypeptide having a polyester degrading activity and uses thereof
PH12014502669B1 (en) Therapeutic agent or prophylactic agent for dementia
MX2020010399A (en) 3-epimerase.
MX371018B (en) Polypeptides having transgalactosylating activity.
MX2018000064A (en) Composition comprising multiple populations of microcapsules comprising perfume.
MX2014008774A (en) Perfume systems.
MX2015014665A (en) Fragrance materials.
MX368688B (en) Intein-modified proteases, their production and industrial applications.
MX357202B (en) Virus like particle composition.
GB201211142D0 (en) Microcapsules
EA201291352A1 (en) PRODUCT CONTAINING STEVE
MX2016005205A (en) Cmp-containing, high protein denatured whey protein compositions, products containing them, and uses thereof.
TW201612108A (en) Method for forming basic nickel carbonate
MX346404B (en) Encapsulates.
RS54678B1 (en) Smoking article comprising menthol
EA201490253A1 (en) FROZEN CONFECTIONERY PRODUCT WITH GEL COATING
IN2015MN00027A (en)
GB201303865D0 (en) Pharmaceutical composition and method of inhibiting of production or amplifyingelimination of P24 protein
MX2015001542A (en) Method.
IN2014DN08496A (en)